To validate that HEXB catalyzes paucimannosidic protein formation in CRC cells, we used a pharmacological Hex inhibitor (M31850) (55) (Fig. 3D) in LIM2405 cells with the aim to block the first step of the truncation pathway in which paucimannosidic proteins are formed (Fig. 1E). Here, HEXB is linked to colorectal carcinoma.